Audentes begins Phase I/II run-in study of AT342 to treat Crigler-Najjar Syndrome

US-based biotechnology firm Audentes Therapeutics has begun the run-in study (LUSTRO) for Phase I/II clinical trial (VALENS) of AT342 for the treatment of patients with Crigler-Najjar Syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news